Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy for renal cell carcinoma.

Ivar Bleumer1, Egbert Oosterwijk, Pieter De Mulder

  • 1Department of Urology, University Medical Center, St Radboud, Geert Grooteplein 10, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.

European Urology
|June 20, 2003
PubMed
Summary

Renal cell carcinoma (RCC) is a rising kidney cancer. While current treatments have limited success, immunotherapy shows promise for advanced RCC, offering a survival benefit with fewer side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predicting tumour and organ dose in α-radiopharmaceutical therapy: a <sup>89</sup>Zr-based dosimetric approach for <sup>225</sup>Ac.

European journal of nuclear medicine and molecular imaging·2026
Same author

Single-Use vs Reusable Catheters for Intermittent Catheterization in Patients With Urinary Retention: The COMPARE Randomized Clinical Trial.

JAMA network open·2026
Same author

From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.

Drugs - real world outcomes·2026
Same author

European Reference Networks - a flagship activity of the EU in the field of rare and complex diseases: from 2017 to 2025.

Orphanet journal of rare diseases·2026
Same author

Impact of Heterogeneous DNA Methylation on the Accuracy of Quantitative Methylation-Specific PCR for Detecting DNA Hypermethylation in Prostate Cancer.

International journal of molecular sciences·2026
Same author

Impact of Metastatic Hormone-sensitive Prostate Cancer Treatments on Health-related Quality of Life: A Systematic Review and Network Meta-analysis.

European urology focus·2025

Area of Science:

  • Oncology
  • Immunology
  • Nephrology

Background:

  • Renal cell carcinoma (RCC) is the most common kidney cancer, with increasing incidence, often detected incidentally.
  • Metastatic RCC (mRCC) carries a poor prognosis, with traditional therapies yielding low response rates (2-6%).
  • Spontaneous remissions suggest a role for immune mechanisms in RCC's natural history.

Purpose of the Study:

  • To review current immunotherapeutical modalities for advanced RCC.
  • To explore novel immunotherapeutic approaches for RCC treatment.
  • To highlight the potential of targeted immunotherapies with improved specificity and reduced toxicity.

Main Methods:

  • Review of existing literature on cytokine-based therapies for mRCC.
  • Analysis of data from clinical trials evaluating non-specific cytokine regimens (e.g., IL-2, IFN-alpha).

Related Experiment Videos

  • Exploration of emerging immunotherapeutic strategies based on tumor-immunology and tumor-associated antigens.

    • Main Results:

    • Cytokine-based therapies for mRCC show an overall response rate of approximately 15%, with 5% complete responses.
    • Cytokine treatments offer a significant survival benefit for a subset of patients.
    • Current immunotherapies have a significant toxicity profile.

    Conclusions:

    • Enhanced understanding of tumor-immunology is driving the development of more specific immunotherapies.
    • New approaches targeting tumor-associated antigens offer potential for increased efficacy and reduced side effects in advanced RCC.
    • Immunotherapy represents a promising avenue for improving outcomes in patients with advanced renal cell carcinoma.